Feb 28 (Reuters) - Endo International Plc reported a 15.6 percent rise in quarterly revenue on Tuesday, largely driven by demand for its newly launched generic drugs, quetiapine and ezetimibe.
The Dublin, Ireland-based drugmaker’s net loss attributable to shareholders widened to $3.34 billion, or $14.98 per share, in the fourth quarter ended Dec. 31, from $118.46 million, or 53 cents per share, a year earlier.
The company took a $3.5 billion asset impairment charge in the latest quarter, related to its generics reporting unit.
Total revenue rose to $1.24 billion from $1.07 billion.
Quetiapine is an anti-psychotic drug and ezetimibe is used to treat cholesterol.
Reporting by Natalie Grover in Bengaluru; Editing by Martina D'Couto